Live News Reader

Some of the articles presented on this website are accessed through RSS feeds from third-party sources that are not necessarily part of the Histiocytosis Association. While we try to select appropriate feeds to prevent objectionable content from being displayed, the presence of any article does not indicate endorsement or recommendation by the Histiocytosis Association.

If you know of a histio-related article that isn't shown here, please send the article to outreach@histio.org.

Erdheim-Chester disease - Google News
This RSS feed URL is deprecated
This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news
Monday, December 11, 2017 12:52:16 AM

Vemurafenib Effective in BRAF-mutated Erdheim-Chester Disease and Langerhans Cell Histiocytosis - Cancer Therapy Advisor

Cancer Therapy Advisor

Vemurafenib Effective in BRAF-mutated Erdheim-Chester Disease and Langerhans Cell Histiocytosis
Cancer Therapy Advisor
Although patients with ECD and LCH frequently have BRAFV600 mutations and respond to BRAFV600 inhibitor therapy, there was previously a lack of data describing long-term efficacy and safety. Vemurafenib confers a durable and clinically beneficial ...


Thursday, November 30, 2017 1:39:52 PM

Leukemia & Lymphoma Society Invests $46M in Research Funding Worldwide - Lymphoma News Today

Lymphoma News Today

Leukemia & Lymphoma Society Invests $46M in Research Funding Worldwide
Lymphoma News Today
Moreover, the millionaire investment reflects the increase in scientific interest for precision medicine, which also is being investigated for its potential to target genetic mutations. Earlier this month, the FDA approved Zelboraf (vemurafenib), a ...


Thursday, November 30, 2017 3:13:56 PM

Biotech Stocks Facing FDA Decision In December - Markets Insider

Biotech Stocks Facing FDA Decision In December
Markets Insider
Roche's Zelboraf, which received thumbs up from the FDA on November 6th, is the first drug to be approved for Erdheim-Chester Disease, a rare cancer of the blood. Innovative Health Solutions' NSS-2 Bridge, which received FDA clearance on November 15th ...


Wednesday, November 29, 2017 7:23:13 PM

FDA Approves Zelboraf for Treatment of a Rare Cancer - Lexology

FDA Approves Zelboraf for Treatment of a Rare Cancer
Lexology
On November 6th, 2017, the U.S. Food and Drug Administration (FDA) approved the drug Zelboraf (vemurafenib), for the treatment of Erdheim-Chester Disease (ECD)[1]. The FDA approved Zelboraf under Priority Review, Breakthrough Therapy, and Orphan Drug ...


Sunday, November 19, 2017 12:15:00 PM

FDA approves first treatment for certain patients with Erdheim-Chester Disease, a rare blood cancer - FDA.gov

Medscape

FDA approves first treatment for certain patients with Erdheim-Chester Disease, a rare blood cancer
FDA.gov
The U.S. Food and Drug Administration today expanded the approval of Zelboraf (vemurafenib) to include the treatment of certain adult patients with Erdheim-Chester Disease (ECD), a rare cancer of the blood. Zelboraf is indicated to treat patients whose ...
First Tx for Erdheim-Chester Disease, a Rare Blood Cancer
FDA Approves Zelboraf (Vemurafenib) for Erdheim-Chester Disease with BRAF V600 Mutation
First-Ever FDA Approval for Erdheim-Chester Disease
 - -

Monday, November 06, 2017 11:39:27 AM

The Leukemia & Lymphoma Society® (LLS) Funds $46 Million in New Research to Find Cures - Markets Insider

The Leukemia & Lymphoma Society® (LLS) Funds $46 Million in New Research to Find Cures
Markets Insider
Earlier this month, the FDA approved a therapy for a very rare blood cancer called Erdheim-Chester disease (ECD). The therapy, vemurafenib (Zelboraf), previously approved to treat a type of melanoma, works by targeting a mutation of the BRAF gene ...


Monday, November 20, 2017 4:07:57 PM

High Red Meat Intake and Cancer - Cancer Therapy Advisor

Cancer Therapy Advisor

High Red Meat Intake and Cancer
Cancer Therapy Advisor
FDA Approves Trastuzumab-dkst as First Biosimilar for HER2+ Breast and GI Cancers · Surgery May Be Superior to Stereotactic Body Radiation Therapy for Early Stage NSCLC · Vemurafenib Effective in BRAF-mutated Erdheim-Chester Disease and Langerhans Cell ...


Saturday, December 02, 2017 1:33:45 PM

FDA Approves Vemurafenib for Treating Erdheim-Chester Disease - Cancer Network

Cancer Network

FDA Approves Vemurafenib for Treating Erdheim-Chester Disease
Cancer Network
Erdheim–Chester disease originates in the bone marrow and is characterized by the abnormal multiplication of histiocytes, which can invade normal tissue and organs, including the brain, heart, lungs, and others. Each year the disease is estimated to ...


Thursday, November 09, 2017 3:29:33 PM

FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester ... - Business Wire (press release)

FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester ...
Business Wire (press release)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application (sNDA) and ...
Erdheim-Chester Disease Treatment Gets FDA Priority Review and Breakthrough Therapy Designation
FDA Grants Zelboraf Priority Review for Rare Blood Disease


Monday, August 07, 2017 9:01:38 AM

Share with Others

© Histiocytosis Association, Inc.
332 North Broadway, Pitman, New Jersey  08071 USA
Phone: +1 856-589-6606 | Fax: +1 856-589-6614
| info@histio.org
Privacy | DisclaimerState Fundraising Notices 
Tax ID: 22-2827069 | Contact Us | Site Map
Follow Me on Pinterest   


¿No Habla Inglés? Si usted puede escribirme sus preguntas y preocupaciones a la dirección de correo electrónico: outreach@histio.org. Nosotros podremos responderle tan pronto nos sea possible. Gracias!